RecruitingNCT07448935

One Gene, Two Diseases: the Pathologic Role of IGLV1-44 in AL Amyloidosis and POEMS

Sponsor

Fondazione IRCCS Policlinico San Matteo di Pavia

Enrollment

100 participants

Start Date

Nov 28, 2025

Study Type

OBSERVATIONAL

Conditions

Multiple Myeloma AL Amyloidosis POEMS Syndrome

Summary

By detailed sequence analysis and subsequent biophysical characterization of prototypic light chains, this project aims to identify sequence fingerprints in IGLV1-44 light chains leading to AL amyloidosis and POEMS syndrome. This understanding might help improve the risk stratification and early diagnosis of patients overexpressing pathologic IGLV1-44 LCs. Moreover, the development of nanobodies efficient in recognizing and stabilizing IGLV1-44 light chains which exert direct toxicity in cardiac AL amyloidosis and POEMS syndrome might form the basis for future development of therapeutic agents capable of counteracting IGLV1-44 light chain proteotoxicity.

Eligibility

Min Age: 18 YearsMax Age: 99 Years

Plain Language Summary

Simplified for easier understanding

This research study is investigating a specific gene called IGLV1-44 and its role in two different rare diseases: AL amyloidosis (where abnormal protein deposits damage organs) and POEMS syndrome (a rare blood disorder causing nerve damage and other complications). Both diseases involve abnormal plasma cells producing unusual antibody proteins, and researchers want to understand why the same gene is linked to both. **You may be eligible if:** - You are 18 years of age or older - You have been diagnosed with AL amyloidosis, POEMS syndrome, or multiple myeloma (confirmed by biopsy) - You are scheduled for a routine blood draw or bone marrow test as part of your normal care - You are willing to allow your samples and clinical data to be used for research **You may NOT be eligible if:** - You have an undefined or non-AL type of amyloidosis - Your disease has completely responded to treatment - You are under 18 years of age - You are unwilling to consent to research use of your samples Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.